company background image
NEU

Neuren Pharmaceuticals ASX:NEU Stock Report

Last Price

AU$7.96

Market Cap

AU$1.0b

7D

-9.6%

1Y

144.2%

Updated

29 Jan, 2023

Data

Company Financials +

Neuren Pharmaceuticals Limited

ASX:NEU Stock Report

Mkt Cap: AU$1.0b

NEU Stock Overview

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders.

NEU fundamental analysis
Snowflake Score
Valuation0/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Neuren Pharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Neuren Pharmaceuticals
Historical stock prices
Current Share PriceAU$7.96
52 Week HighAU$9.18
52 Week LowAU$3.04
Beta1.6
1 Month Change0.13%
3 Month Change8.59%
1 Year Change144.17%
3 Year Change181.27%
5 Year Change165.33%
Change since IPO7.57%

Recent News & Updates

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Jan 07
Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Recent updates

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Jan 07
Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Sep 06
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

May 31
Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Feb 03
We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

Aug 06
Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

May 05
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Feb 19
Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Jan 04
Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Shareholder Returns

NEUAU PharmaceuticalsAU Market
7D-9.6%-4.4%0.6%
1Y144.2%-25.2%3.5%

Return vs Industry: NEU exceeded the Australian Pharmaceuticals industry which returned -25.2% over the past year.

Return vs Market: NEU exceeded the Australian Market which returned 3.5% over the past year.

Price Volatility

Is NEU's price volatile compared to industry and market?
NEU volatility
NEU Average Weekly Movement5.8%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement8.5%
10% most volatile stocks in AU Market15.7%
10% least volatile stocks in AU Market3.5%

Stable Share Price: NEU is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: NEU's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001n/aJon Pilcherhttps://www.neurenpharma.com

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes.

Neuren Pharmaceuticals Limited Fundamentals Summary

How do Neuren Pharmaceuticals's earnings and revenue compare to its market cap?
NEU fundamental statistics
Market CapAU$1.00b
Earnings (TTM)-AU$6.88m
Revenue (TTM)AU$3.20m

313.6x

P/S Ratio

-145.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NEU income statement (TTM)
RevenueAU$3.20m
Cost of RevenueAU$7.17m
Gross Profit-AU$3.97m
Other ExpensesAU$2.92m
Earnings-AU$6.88m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.055
Gross Margin-124.15%
Net Profit Margin-215.33%
Debt/Equity Ratio0%

How did NEU perform over the long term?

See historical performance and comparison